# Nihon Medi-Physics

Source: https://nuclide.cc/companies/nihon-medi-physics/  
Nuclide record `nihon-medi-physics` (Company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Japan's largest maker of radioactive tracers for scans, now wholly owned by GE HealthCare.

## Summary

Nihon Medi-Physics was incorporated on 20 March 1973 and is based at Shinsuna, Koto-ku, Tokyo. Its stated business is the "research, development, manufacture, sale, purchase and import/export of radioactive pharmaceuticals". It holds the Japanese approvals for several of the diagnostic agents in this corpus, each dated in the PMDA's own English list: DaTscan (ioflupane I-123) in September 2013, Vizamyl (flutemetamol F-18) in September 2017 and Axumin (fluciclovine F-18) in March 2021.

Ownership changed in 2025. GE HealthCare had held 50 per cent since acquiring Amersham in 2004; on 31 March 2025 it completed the purchase of the remaining 50 per cent from Sumitomo Chemical, making NMP a wholly owned subsidiary and giving GE HealthCare direct control of the Japanese radiopharmaceutical channel. In September 2025 Lantheus and GE HealthCare announced an exclusive licence for PYLARIFY (piflufolastat F-18) in Japan, which is how a US PSMA tracer reaches the Japanese market.

## Fields

- Kind: Company
- Last checked: 2026-09-22
- Also known as: Nihon Medi-Physics Co., Ltd.; NMP
- HQ: Tokyo, Japan
- Type: radiopharma
- Website: https://www.nmp.co.jp/eng/

## Sources

- Company overview (incorporated 20 March 1973; shareholder GE HealthCare): https://www.nmp.co.jp/eng/profile/about.html
- GE HealthCare completes acquisition of Nihon Medi-Physics: https://www.gehealthcare.com/en-us/about/newsroom/press-releases/ge-healthcare-completes-acquisition-of-nihon-medi-physics-nmp-a-leading-radiopharmaceutical-company-in-japan
- PMDA list of approved drugs (April 2004 onwards): https://www.pmda.go.jp/files/000281190.pdf

## Connected records

- companies: [GE HealthCare](https://nuclide.cc/companies/ge-healthcare/)
- drugs: [Fluciclovine F-18](https://nuclide.cc/drugs/fluciclovine-f18/), [Flutemetamol F-18](https://nuclide.cc/drugs/f-18-flutemetamol/), [Ioflupane I-123](https://nuclide.cc/drugs/i-123-ioflupane/), [Piflufolastat F-18 / Pylarify TruVu](https://nuclide.cc/drugs/pylarify/)
- institutions: [Japanese Society of Nuclear Medicine](https://nuclide.cc/institutions/jsnm/), [Pharmaceuticals and Medical Devices Agency](https://nuclide.cc/institutions/pmda/)
- isotopes: [Fluorine-18](https://nuclide.cc/isotopes/f-18/), [Iodine-123](https://nuclide.cc/isotopes/i-123/)

---
JSON: https://nuclide.cc/api/v1/entities/nihon-medi-physics.json